[1]
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, et al.
Nomenclature of systemic vasculitides. Proposal of an international
consensus conference. Arthritis Rheum. 1994 Feb;37(2):187-92.
[2]
Kaczmarczyk MS, Jurkiewicz D, Niemczyk S, Rymarz A. Aural
manifestations of antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis-diagnosis, symptoms, Treatment. J Clin
Med. 2024 Jul 23;13(15):4298.
[3]
Cao B, Robinson JE, Winget M, Hunt MH, Carlson R, et al. Thorpe CT.
Infection prophylaxis among patients with antineutrophil cytoplasmic
antibody (ANCA) vasculitis: a scoping review. Clin Rheumatol. 2024
Jul 25.
[4]
Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum
2020. Am J Kidney Dis. 2020 Jan;75(1):124-137.
[5]
Takeda S, Watanabe-Kusunoki K, Nakazawa D, Kusunoki Y, Nishio S, et
al. The pathogenicity of BPI-ANCA in a patient with systemic
vasculitis. Front Immunol. 2019 Jun 12; 10:1334.
[6]Konda R, Rajasekaran A, Rizk DV. Antineutrophil cytoplasmic
antibody-associated vasculitis. Curr Opin Nephrol Hypertens. 2024 Sep
1;33(5):503-511.
[7]田新平,赵丽柯,姜振宇等.抗中性粒细胞胞质抗体相关血管炎诊疗规范[J].中华内科杂志,
2022,61(10) : 1128-1135.
[8]
Kidney disease: Improving Global Outcomes (KDIGO) ANCA vasculitis
work group. KDIGO 2024 clinical practice guideline for the management
of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Kidney Int. 2024 Mar;105(3S): S71-S116.
[9]
Paroli M, Gioia C, Accapezzato D. New Insights into Pathogenesis and
Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond.
Antibodies (Basel). 2023 Mar 21;12(1):25.
[10]
Chung SA, Langford CA, Maz M, Abril A, Gorelik M, et al. 2021
American College of Rheumatology/Vasculitis Foundation Guideline for
the Management of Antineutrophil Cytoplasmic Antibody-Associated
Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-1383.
